Consensus Spyre Therapeutics, Inc.

Equities

SYRE

US00773J2024

Real-time Estimate Cboe BZX Other stock markets 02:46:45 2024-05-03 pm EDT			5-day change	1st Jan Change
36.14 ^USD	-0.37%		+8.28%	+68.87%

May. 02	Baird Starts Spyre Therapeutics With Outperform Rating, $50 Price Target	MT
Apr. 19	Sector Update: Health Care Stocks Steady Pre-Bell Friday	MT

Evolution of the average Target Price on Spyre Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

b73768a5cc2094363e5697fbe79a7.nM_QjI_GMNsKjDACH5XUFHxqmYBtbZV3LoyQBQzR7Bk.qfqYwuWwCZxzz3ZjUK2gWUsp_esgKPoHXtjZKGWQvWrkpbjE16IJnHvZdQ~cac35fc47da3c3d3056b0c8b8ce626ea

Analyst Recommendations on Spyre Therapeutics, Inc.

Baird Starts Spyre Therapeutics With Outperform Rating, $50 Price Target	May. 02	MT
Stifel Adjusts Spyre Therapeutics' Price Target to $54 From $36, Maintains Buy Rating	Mar. 26	MT
Wells Fargo Upgrades Spyre Therapeutics to Overweight From Equalweight, Raises Price Target to $35 From $12	Mar. 01	MT
BTIG Initiates Spyre Therapeutics With Buy Rating, Price Target is $32	Dec. 20	MT
Stifel Adjusts Price Target on Spyre Therapeutics to $27 From $23, Keeps Buy Rating	Dec. 18	MT
Jefferies Initiates Spyre Therapeutics at Buy Rating With $31 Price Target	Dec. 11	MT
Wells Fargo Adjusts Price Target on Aeglea BioTherapeutics to $0.50 From $0.35, Maintains Equal-Weight Rating	23-08-16	MT
Stifel Initiates Aeglea BioTherapeutics With Buy Rating, $0.90 Price Target	23-07-25	MT
LifeSci Capital Downgrades Aeglea BioTherapeutics to Market Perform From Outperform	23-04-12	MT
JonesTrading Downgrades Aeglea BioTherapeutics to Hold From Buy	23-04-12	MT
Piper Sandler Lifts Aeglea BioTherapeutics to Overweight From Neutral, Price Target to $1.50 From $1	22-10-28	MT
Wells Fargo Lifts Aeglea BioTherapeutics to Overweight From Equalweight, Price Target to $2 From $1.50	22-10-28	MT
Needham Downgrades Aeglea BioTherapeutics to Hold From Buy	22-06-03	MT
Piper Sandler Downgrades Aeglea BioTherapeutics to Neutral From Overweight, Cuts Price Target to $1 From $4, Shares Dive 46%	22-06-02	MT
HC Wainwright Downgrades Aeglea BioTherapeutics to Neutral From Buy, Cuts Price Target to $1 From $17	22-06-02	MT
Piper Sandler Adjusts Price Target for Aeglea BioTherapeutics to $4 From $7, Maintains Overweight Rating	22-05-23	MT
Piper Sandler Adjusts Aeglea BioTherapeutics' Price Target to $7 From $9, Reiterates Overweight Rating	22-05-09	MT
HC Wainwright Adjusts Price Target on Aeglea BioTherapeutics to $17 From $20, Reiterates Buy Rating	22-05-06	MT
AEGLEA BIOTHERAPEUTICS : HC Wainwright Adjusts Aeglea BioTherapeutics' Price Target to $15 from $17, Keeps Buy Rating	20-11-09	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

36.27 USD

Average target price

43.14 USD

Spread / Average Target

+18.95%

High Price Target

54 USD

Spread / Highest target

+48.88%

Low Price Target

31 USD

Spread / Lowest Target

-14.53%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Spyre Therapeutics, Inc.

Baird
Stifel Nicolaus
Wells Fargo Securities
BTIG
Jefferies & Co.
LifeSci Capital
JonesTrading Institutional Services
Piper Sandler
Needham & Co.
HC Wainwright

Ratings for Spyre Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar